AMPH , INDV , PCRX

This week, we use AAII’s A+ Investor Stock Grades to provide insight into three pharmaceutical stocks. With increased focus on the pharmaceutical industry and surging medicines, should you consider the three stocks of Amphastar Pharmaceuticals Inc. (AMPH), Indivior Pharmaceuticals Inc. (INDV) and Pacira BioSciences Inc. (PCRX).

Pharmaceutical Stocks Recent News

Global medicine use is expanding steadily, with China leading the way and mature markets leveling off. A report by the IQVIA Institute for Human Data Science details that total usage is expected to approach four trillion defined daily doses by 2030. Global spending on medicines is projected to exceed $2.6 trillion by 2030, rising between 5% and 8% annually. China has been the fastest-growing market since 2020 and is forecast to nearly double its usage by 2030 relative to 2020 levels, while North America, Western Europe and Japan are expected to grow more slowly. Once population is factored in, global medicine use is projected to grow just 1.9% annually over the next five years, versus 2.7% growth unadjusted for population. North American per capita medicine use is projected to grow only 0.9% per year through 2030.

As the report points out, the spending story is concentrated in a handful of wealthy countries and a few therapy areas. The U.S. and 14 other high-income countries account for 76% of global spending growth through 2030, while emerging pharmaceutical markets are expected to add about $121 billion over the same period. Oncology, immunology, diabetes and obesity drugs are the biggest contributors to that growth, driven by a steady flow of innovative products, mainly lipid regulators. Given these global trends, should you invest in Amphastar Pharmaceuticals, Indivior Pharmaceuticals and Pacira BioSciences?

Sign Up to Receive a Free Special Report That Shows How A+ Investor Grades Can Help You Make Investment Decisions

Grading Pharmaceutical Stocks With AAII’s A+ Stock Grades

 When analyzing a company, it is helpful to have an objective framework that allows you to compare companies in the same way. This is why AAII created the A+ Stock Grades, which evaluate companies across five factors that research and real-world investment results indicate to identify market-beating stocks in the long run: value, growth, momentum, earnings estimate revisions (and surprises) and quality.

Using AAII’s A+ Stock Grades, the following table summarizes the attractiveness of three pharmaceutical stocks—Amphastar Pharmaceuticals, Indivior Pharmaceuticals and Pacira BioSciences—based on their fundamentals.

AAII’s A+ Stock Grade Summary for Three Pharmaceutical Stocks

What the A+ Stock Grades Reveal

Amphastar Pharmaceuticals Inc. (AMPH) is a specialty pharmaceutical company operating in the U.S., China and France. It offers finished pharmaceutical products and active pharmaceutical ingredients for hospital, retail and institutional markets. Amphastar Pharmaceuticals manufactures a broad range of drug products, including epinephrine, naloxone, enoxaparin and glucagon, serving acute care and emergency medicine markets. It also produces and sells active pharmaceutical ingredients through its subsidiary Armstrong Pharmaceuticals, with manufacturing facilities strategically located across its regions to support its global supply chain. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Amphastar Pharmaceuticals has a Value Grade of A, based on its Value Score of 85, which is deep value. The Value Grade is the percentile rank of the average of the percentile ranks of the price-to-sales (P/S) ratio, price-earnings (P/E) ratio, price-to-book-value (P/B) ratio, price-to-free-cash-flow (P/FCF) ratio, shareholder yield and the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EBITDA). For these value metrics, a lower rank is more attractive. The company has a price-to-free-cash-flow ratio of 7.7, ranking in the 18th percentile among all U.S.-listed stocks. It also has a shareholder yield of 7.0%, ranking in the 11th percentile.

The company has a Growth Grade of A, which is very strong. The components of the Growth Composite Score consider a company’s success in growing sales on a year-over-year and long-term annualized basis and its ability to consistently generate positive cash from its core operations. Amphastar Pharmaceuticals has a five-year annualized sales growth rate of 15.5% and has generated positive annual cash from operations in the past five consecutive years.

Amphastar Pharmaceuticals has a Momentum Grade of B, based on its Momentum Score of 79. This means that the stock’s momentum is strong in terms of its weighted relative strength over the last four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters, with the most recent quarterly price change given a weight of 40% and each of the three previous quarters given a weight of 20%. The ranks are 91, 34, 18 and 83, sequentially from the most recent quarter, with higher ranks signaling stronger price momentum. The weighted four-quarter relative price strength is 6.1%.

Indivior Pharmaceuticals Inc. (INDV) is a global specialty pharmaceutical company operating in the U.S., Europe and Asia. It offers prescription medicines and related treatment solutions focused on addiction and mental illness for patients, utilizing healthcare providers and treatment programs worldwide. Indivior Pharmaceuticals provides a broad range of addiction treatment medicines and patient support services, including patient assistance programs, healthcare provider education and treatment access initiatives. It also conducts research and development (R&D) activities aimed at expanding its pipeline of treatments for opioid use disorder, alcohol use disorder and serious mental illness. The company was founded in 2014 and is headquartered in Richmond, Virginia.

Indivior Pharmaceuticals has a Value Grade of A, based on its Value Score of 82, which is deep value. The company’s price-earnings ratio is 12.8, ranking in the 31st percentile, and its shareholder yield is 4.8%, ranking in the 17th percentile.

Earnings estimate revisions indicate how analysts view a firm’s short-term profits. The company has an Earnings Estimate Revisions Grade of B, based on a score of 73, which is positive. The grade is based on the statistical significance of its latest two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months. The company reported a positive earnings surprise of 24.8% for second-quarter 2026, and in the prior quarter reported a positive earnings surprise of 45.5%. Over the last three months, the consensus earnings estimate for third-quarter 2026 has increased from $0.971 to $1.119 per share, while the consensus earnings estimate for full-year 2026 has increased from $3.825 to $4.409 per share.

The company has a Quality Grade of A, based on a score of 93, which is very strong. Higher-quality stocks possess traits associated with upside potential and reduced downside risk. The Quality Grade is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit to assets, buyback yield, change in total liabilities to assets, accruals to assets, Z double prime bankruptcy risk (Z) score and F-Score. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

Indivior Pharmaceuticals ranks strongly in terms of its return on assets and buyback yield. Its return on assets is 26.5%, ranking in the 97th percentile, and its buyback yield is 4.8%, ranking in the 89th percentile.

Don’t Miss Your Free Report — Sign Up Here!

Pacira BioSciences Inc. (PCRX) is a specialty pharmaceutical company operating primarily in the U.S. It offers non-opioid pain management and regenerative health solutions for patients, surgeons and healthcare providers across a broad range of surgical and orthopedic settings. The company provides a broad range of pain management therapies utilizing its proprietary DepoFoam drug delivery technology, which enables extended release of medications at the site of administration. It also conducts R&D activities aimed at expanding its non-opioid pain management pipeline. The company was founded in 2006 and is headquartered in Tampa, Florida.

Pacira BioSciences has a Growth Grade of A, which is very strong. It has a five-year annualized sales growth rate of 11.1% and has generated positive annual cash from operations in the past five consecutive years.

The company has a Momentum Grade of A, based on its Momentum Score of 91. This means that the stock’s momentum is very strong in terms of its weighted relative strength over the last four quarters. The ranks are 94, 65, 68 and 41, sequentially from the most recent quarter. The weighted four-quarter relative price strength is 15.2%.

Pacira BioSciences has a Quality Grade of A, based on a score of 95, which is very strong. The company ranks strongly in terms of its buyback yield and F-Score. Its buyback yield is 13.2%, ranking in the 97th percentile, and its F-Score is 8, ranking in the 92nd percentile. The F-Score is a number between 0 and 9 that assesses the strength of a company’s financial position based on its profitability, leverage, liquidity and operating efficiency.

Discussion